BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200406
DTEND;VALUE=DATE:20200407
DTSTAMP:20200211T235602Z
CREATED:20200211T235220Z
LAST-MODIFIED:20200211T235602Z
UID:39312-1586131200-1586217599@globalbiodefense.com
SUMMARY:Proposals Due: Influenza Data Processing and Outreach
DESCRIPTION:If your small business has strong experience with scientific data processing and outreach\, consider sending a contract proposal to establish an Influenza Data Processing and Communication Center (iDPCC). \nThis solicitation recompetes and renames the current influenza DPCC contract to support NIAID’s Centers of Excellence for Influenza Research and Response (CEIRR) network. \nSubmit your proposal by April 6\, 2020. If you have any questions\, send them to the contracting officer listed in the solicitation no later than March 4\, 2020. \nLearn more about this funding opportunity in Funding News \n  \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status. \n 
URL:https://globalbiodefense.com/event/proposals-due-influenza-data-processing-and-outreach/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200408T140000
DTEND;TZID=America/New_York:20200408T153000
DTSTAMP:20200402T171318Z
CREATED:20200402T170907Z
LAST-MODIFIED:20200402T171318Z
UID:42524-1586354400-1586359800@globalbiodefense.com
SUMMARY:NASEM Webinar: The Supply Chain and COVID-19
DESCRIPTION:COVID-19 has had a profound impact on supply chains for many different critical products worldwide. The pandemic has created major changes in freight flows and has challenged the ability to deliver both medical supplies and food. \nThe National Academies’ Transportation Research Board (TRB) is hosting a webinar on Wednesday\, April 8\, 2020\, from 2:00 to 3:30 PM Eastern that will explore the impacts of COVID-19 on the supply chain and logistics industries. Presenters will discuss lessons learned from past freight transportation and supply chain disruptions\, identify research that has been done to address resilience in the supply chain\, describe how to mitigate the economic impacts of these disruptions\, and provide commentary on current supply chain disruptions due to COVID-19. The webinar is free to attend\, but registration is required. You can follow the conversation on Twitter by using #COVID19 and #TRBwebinar. \nWebinar Participants\n• Moderated by: Mike Meyer\, WSP\, Principal Investigator for NCFRP Research Report 39: Freight Transportation Resilience in Response to Supply Chain Disruptions\n• Paul Bingham\, IHS Markit\, expert in supply chain logistics\, freight transportation\, and transportation economics\n• Anne Strauss-Wieder\, North Jersey Transportation Planning Authority\, expert in supply chain and freight movement\, transportation policy\, and maritime transportation \nWebinar Outline \n1. How the supply chain industry has responded to past disruptions\n2. Lessons learned from past disruptions and best practices for a resilient supply chain\n3. How supply chain and logistics managers can respond to disruptions from COVID-19\n4. Question and answer session\nThe first 60 minutes of the webinar will be for presentations and the final 30 minutes will be reserved for audience questions. \nResources about supply chain and logistics from TRB: \n\nNCFRP Research Report 39: Freight Transportation Resilience in Response to Supply Chain Disruptions\nE-Circular E-C259: International Transportation and Economic Development Conference 2018\nTR News article: Supply Chain Business Continuity\nTR News article: Aviation’s Evolving Role in a Changing Climate\nTRB Director Neil Pedersen’s message regarding COVID-19
URL:https://globalbiodefense.com/event/nasem-webinar-the-supply-chain-and-covid-19/
LOCATION:Virtual-Webcast
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T233435Z
CREATED:20200211T233017Z
LAST-MODIFIED:20200211T233435Z
UID:39300-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Development of Radiation/Nuclear Medical Countermeasures
DESCRIPTION:Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs) HHS-NIH-NIAID-BAA2020-1\nThis research topic call for proposals is part of the 2020 NIAID Omnibus Broad Agency Announcement. \nIt supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries resulting from exposure to ionizing radiation from a radiological or nuclear incident\, thereby leading to a reduction in radiation-associated morbidities and mortalities. \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nRead more about this opportunity in Funding News.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-development-of-radiation-nuclear-medical-countermeasures/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T233920Z
CREATED:20200211T233539Z
LAST-MODIFIED:20200211T233920Z
UID:39302-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Therapeutic Products for Biodefense\, AMR Infections\, and Emerging Infectious Diseases
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 004: Development of Therapeutic Products for Biodefense\, Anti-Microbial Resistant (AMR) Infections\, and Emerging Infectious Diseases\nSupports development of promising new therapeutics to address infections caused by NIAID Category A\, B\, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 \, including optimization\, preclinical (investigational new drug-enabling)\, and clinical trials that include Phase I and Phase II studies. \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nRead more on this opportunity in Funding News. \n  \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-therapeutic-products-for-biodefense-amr-infections-and-emerging-infectious-diseases/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T234620Z
CREATED:20200211T234423Z
LAST-MODIFIED:20200211T234620Z
UID:39307-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases\nSupports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp.\, Pseudomonas aeruginosa\, Francisella tularensis\, Yersinia pestis\, and E. coli\, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (e.g.\, Eastern Equine Encephalitis) and bunyaviruses (e.g.\, Rift Valley Fever Virus). \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nLearn more about this opportunity in here. \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-advanced-development-of-vaccine-candidates-for-biodefense-and-emerging-infectious-diseases/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T235015Z
CREATED:20200211T234714Z
LAST-MODIFIED:20200211T235015Z
UID:39309-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Advanced Development of Diagnostics for Biothreats and EID
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases\n\nSupports advancing the development of novel\, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness.\nNumber of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined).\nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time\n\nLearn more about this BAA in Funding News. \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20200415T123000
DTEND;TZID=America/Los_Angeles:20200415T140000
DTSTAMP:20240623T231227Z
CREATED:20200408T174031Z
LAST-MODIFIED:20240623T231227Z
UID:42787-1586953800-1586959200@globalbiodefense.com
SUMMARY:Protecting Older Adults from the Harms of Social Isolation and Providing a Continuum of Care During COVID-19
DESCRIPTION:Join Trust for America’s Health (TFAH) on Wednesday\, April 15th for the webinar Protecting Against the Harms of Social Isolation During COVID-19. \nThe ongoing COVID-19 crisis presents unique challenges for the public health and aging sectors. While social distancing protects older adults who are at higher risk for complications from the virus\, the practice can exacerbate social isolation\, a longstanding issue for this population. \nAttendees will learn about the consequences of social isolation\, how the aging services sector has adapted its delivery models\, promising practices from the field and the importance of working with public health partners to address the needs of older adults.
URL:https://globalbiodefense.com/event/protecting-older-adults-from-the-harms-of-social-isolation-and-providing-a-continuum-of-care-during-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200415T170000
DTEND;TZID=America/New_York:20200415T183000
DTSTAMP:20240623T192248Z
CREATED:20200414T182247Z
LAST-MODIFIED:20240623T192248Z
UID:43055-1586970000-1586975400@globalbiodefense.com
SUMMARY:APHA and National Academy of Medicine Webinar: Crisis Standards of Care During COVID-19
DESCRIPTION:Brought to you by the American Public Health Association and the National Academy of Medicine\, this webinar series is exploring the state of the science surrounding the current outbreak of COVID-19 in the United States and globally\, with a focus on the emerging evidence on how to best mitigate its impact. Hear from trusted experts in such fields as public health\, infectious disease\, risk communication\, and crisis standards of care. \nWebinar #4: Crisis Standards of Care During COVID-19\nWednesday\, April 15\, 5-6:30 p.m. ET \nThe fourth COVID-19 Conversations webinar will provide an overview of crisis standards of care during a pandemic\, challenges for adapting such standards to rapidly evolving clinical care guidelines\, practical considerations for state health departments and hospital systems\, and ethical considerations for decision-making while enacting crisis standards of care. \nThe expert panel for this webinar includes: \n\nJohn L. Hick\, MD\, is a faculty emergency physician at Hennepin County Medical Center and an Associate Professor of Emergency Medicine at the University of Minnesota Medical School. He serves as the Associate Medical Director for Hennepin County Medical Services and Medical Director for Emergency Preparedness at HCMC. He is medical advisor to the Minneapolis/St. Paul Metropolitan Medical Response System. He also serves the Minnesota Department of Health as the Medical Director for the Office of Emergency Preparedness and Medical Director for Hospital Bioterrorism Preparedness. He is the founder and past chair of the Minneapolis/St. Paul Metropolitan Health Compact\, a 29-hospital mutual aid and planning group. The regional program was recognized with a $2.5 million competitive HHS preparedness grant in 2007. Hick traveled to Greece as part of a 15-member CDC/HHS team to assist with health care system preparations for the 2004 Summer Olympics. He continues to work with HHS and other agencies on issues of hospital surge capacity planning\, adjusted standards of care in disasters\, and preparedness for nuclear terrorism.\n\n  \n\nRebecca E. Gee\, MD\, is the Secretary of the Louisiana Department of Health\, the state’s largest agency with a budget of $14 billion\, and Gratis Assistant Professor at the LSU Schools of Public Health and Medicine. Her oversight responsibilities include public health and other direct service programs for citizens in needs such as behavioral health\, developmental disabilities\, aging and adult services\, emergency preparedness ad the Medicaid program. Her Medicaid expansion work resulted in an additiona 500\,000+ Louisiana residents being newly insured and the launch of a dashboard to measure access to health care services that has become a national model used in other states. She is an OB/GYN\, trained policy expert and previously served as the director of the Birth Outcomes Initiative\, where she led the charge to decrease infant mortality and prematurity statewide — an effort that in part led to a 25% reduction in infant mortality\, an 85% drop in elective deliveries before 39 weeks and a 10% drop in NICU admissions.\n\n  \n\nJeffrey Kahn\, PhD\, MD\, is the is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics and the inaugural Robert Henry Levi and Ryda Hecht Levi Professor of Bioethics and Public Policy. He is also Professor in the Department of Health Policy and Management of the Johns Hopkins Bloomberg School of Public Health. He works in a variety of areas of bioethics\, exploring the intersection of ethics and health/science policy. Kahn has served on numerous state and federal advisory panels and is currently chair of National Academies of Sciences\, Engineering\, and Medicine’s Board on Health Sciences Policy\, and has previously chaired its committee on the Use of Chimpanzees in Biomedical and Behavioral Research; the committee on Ethics Principles and Guidelines for Health Standards for Long Duration and Exploration Spaceflights; and a committee on the Ethical\, Social\, and Policy Considerations of Mitochondrial Replacement Techniques. He also formerly served as a member of the National Institutes of Health Recombinant DNA Advisory Committee. In addition to committee leadership and membership\, he is an elected member of the National Academy of Medicine and an elected Fellow of The Hastings Center. He was also the founding president of the Association of Bioethics Program Directors. He is a co-principal investigator with Berman Institute faculty member Gail Geller\, ScD\, MHS\, on GUIDE: Genomic Uses in Infectious Disease and Epidemics\, an NIH-funded project to study the largely unexplored ethical\, legal and social implications of genomics as applied to infectious disease.\n\n  \n\nLawrence “Larry” O. Gostin\, JD\, directs the O’Neill Institute for National and Global Health Law and is the founding O’Neil Chair in Global Health Law at Georgetown University. He served as associate dean for research at Georgetown Law from 2004-2008 and is professor of medicine at Georgetown University and professor of public health at Johns Hopkins University. He is director of the World Health Organization Collaborating Center on National and Global Health Law. Among his appointed posts at WHO\, he served on the Director-General’s Advisory Committee on Reforming the World Health Organization\, is on the International Health Regulations Roster of Experts and has served on many WHO expert advisory committees including on the Pandemic Influenza Preparedness Framework and on the WHO/Global Fund Blue Ribbon Expert Panel: The Equitable Access Initiative to develop a global health equity framework. He co-chairs the Lancet Commission on Global Health Law. He served on two global commissions to report on the lessons learned from the 2015 West African Ebola epidemic and was senior advisor to the United Nations Secretary General’s post-Ebola Commission. Gostin also served on the drafting team for the G-17 Summit in Tokyo in 2016\, focusing on global health security and universal health coverage.
URL:https://globalbiodefense.com/event/apha-and-national-academy-of-medicine-webinar-crisis-standards-of-care-during-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200420
DTEND;VALUE=DATE:20200425
DTSTAMP:20200323T183614Z
CREATED:20191219T152600Z
LAST-MODIFIED:20200323T183614Z
UID:35622-1587340800-1587772799@globalbiodefense.com
SUMMARY:POSTPONED | NO NEW DATE - BSL-4 Training: Achieving Data Quality and Integrity in Maximum Containment Laboratories
DESCRIPTION:The FDA and the University of Texas Medical Branch\, Galveston National Laboratory (UTMB) will host this year’s annual training course on how to meet GLP requirements in BSL-4 facilities from April 20-24\, 2020 at the National Institutes of Health (NIH) in Bethesda\, Maryland. \nScientists working to develop Medical Countermeasures (MCMs) against several high-priority biological threat agents are at high risk of aerosol-transmitted laboratory infection and life-threatening disease\, as there are no vaccines or treatments for these agents. Accordingly\, much of the work to develop MCMs for these high-priority agents must be done in high and maximum biosafety level (BSL)-4 laboratories to prevent the agents from being released into the environment\, and to provide maximum safety for the scientists. \nThe unique challenges of BSL-4\nWhile necessary to ensure lab worker safety and prevent accidental release of dangerous pathogens\, BSL-4 environments pose unique challenges to developing MCMs. For example\, data generated to support a regulatory submission to FDA must be collected in accordance with quality systems\, like good laboratory practice (GLP) regulations\, to be useful and reliable\, and to facilitate FDA review to ensure safety and efficacy. \nHowever\, meeting data quality and integrity standards like GLP in a BSL-4 environment is challenging. Current practice is often inconsistent among laboratories due to technological infrastructure\, available internal standard operating procedures\, level of regulatory awareness\, and individual breadth of experience and training. And completing even routine lab tasks in a protective BSL-4 suit can be difficult—imagine\, for example\, trying to pick up a small item\, like a toothpick\, while wearing two pairs of thick gloves. \nTo help address the challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development\, FDA and the University of Texas Medical Branch\, Galveston National Laboratory (UTMB) collaborate to provide an annual training course on how to meet GLP requirements in BSL-4 facilities (“data quality course”). \n\nThis popular course offers a unique opportunity for the regulatory and scientific communities to discuss complex issues in an interactive environment and identify and share best practices for ensuring data quality and integrity in BSL-4 facilities. \n\nIn addition to UTMB and FDA\, other federal partners from the National Interagency Confederation for Biological Research (NICBR) provide support and resources for this course. These partners include: \n\nFrom the National Institutes of Health\n\nOffice of the Director\nNational Institute of Allergy and Infectious Diseases (NIAID)\nNational Cancer Institute (NCI)\n\n\nFrom the Department of Defense\n\nU.S. Army Medical Research and Materiel Command (USAMRMC)\n\n\n\n\nFrom the Department of Homeland Security\n\nNational Biodefense Analysis and Countermeasures Center (NBACC)\n\n\n\nHistory and new additions\nSince the data quality course began in 2013\, it has quickly reached capacity each year. In its first five years\, 269 participants completed the course. \nIn September 2017\, the FDA Medical Countermeasures Initiative (MCMi) renewed the grant  to continue the data quality course for an additional five years\, from 2018-2022. UTMB and FDA will also expand on-demand online offerings\, adding data quality-related good clinical practices (GCP) training and other courses to meet the needs of researchers responding to emerging infectious disease outbreaks. \nCourse description\nThe week-long\, data quality course is designed to help researchers who conduct studies intended to support approval under the Animal Rule\, which may be used to grant marketing approval of certain products when human challenge studies would not be ethical or feasible. \nThe course includes expert lectures and hands-on laboratory activities conducted in BSL-2 and BSL-4 training laboratories to emphasize the differences between biosafety levels\, and the complexity of conducting laboratory activities in a BSL-4 environment. An online training module on GLP regulations (21 CFR Part 58) is included as a course pre-requisite. For additional information\, visit the official UTMB course website \nTopics covered include: \n\nAnimal Rule regulations\, and clinical applications of Animal Rule studies\nAssay validation\nBSL-2/3/4 comparison\, with hands-on simulations\nBSL-4 equipment\, with hands-on work in a BSL-4 training lab\nDisease agent characterization\nGLP regulations\nGood documentation practices\nInstitutional Animal Care and Use Committee (IACUC) protocols\nTelemetry\nSupportive care\nSurrogate endpoints\nTesting facility management\nVeterinary pathology\nIntegration of quality assurance (QA) in BSL-4 studies\nAdvancement of MCMs on the international stage\n\nWho may attend?\nFDA welcomes participants from government\, industry\, and academia. We welcome international participation as well; attendees in previous years have included representatives from international public health agencies. Attendees typically include: \n\nPolicy-makers\nMCM product sponsors (industry)\nQuality assurance personnel\nRegulators\nReviewers\nScientists\nVeterinarians\n\nPre-requisites include GLP and IACUC training that are available to course attendees. \nCourse Cost and Availability\nThere are no registration fees for this FDA-sponsored course\, however\, seats are limited\, and course attendees are invited based upon diversity of roles\, responsibilities\, and organization. Interested participants will be placed on a waitlist once seats are filled. \nRELATED INFORMATION \n\nInformation about the course from UTMB\nSister course: Achieving Data Quality and Integrity in Clinical Trials Involving High-Consequence Pathogens\nPrevious course offerings\nView photos from the 2015 course on Flickr
URL:https://globalbiodefense.com/event/bsl-4-training-achieving-data-quality-and-integrity-in-maximum-containment-laboratories/
LOCATION:National Institutes of Health (NIH)\, Bethesda\, MD\, United States
CATEGORIES:Training
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20200421T130000
DTEND;TZID=Europe/London:20200421T140000
DTSTAMP:20240623T192624Z
CREATED:20200406T161624Z
LAST-MODIFIED:20240623T192624Z
UID:42642-1587474000-1587477600@globalbiodefense.com
SUMMARY:DASA Biosensing Across Wide Areas Phase 2 Launch
DESCRIPTION:Join the Defence and Security Accelerator for a dial-in on 21 April 2020\, 1pm to 2pm. The competition team will provide a short briefing on the Biosensing Across Wide Areas Phase 2 competition followed by an open forum Q&A session. \nOne to Ones\nThere will be two opportunities for One to One dial-in sessions with the competition team: \n\nWednesday 21 April 2020 –  2.30pm to 4pm: Three slots available\nThursday 22 April 2020 – 1pm to 3pm: Four slots available\n\nThese pre-bookable 20 minute one to one slots will be with the competition team to discuss questions specific to your proposal. Slots are on a first come\, first serve basis. \nPlease note: \n\na separate link will be sent to you on your ticket confirmation to register for a one to one slot\ndetails of the dial in will be sent before the meeting commences\nif the event is oversubscribed\, we may place a limitation on the number of attendees from a single organisation\n\n// \nREAD MORE: UK Launches Wide-Area Biosensor Competition
URL:https://globalbiodefense.com/event/dasa-biosensing-across-wide-areas-phase-2-launch/
CATEGORIES:Conference,Industry Day,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/04/97aef6bbedcf01db65e877ee6755e43d.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200424
DTEND;VALUE=DATE:20200425
DTSTAMP:20200222T220028Z
CREATED:20200222T215710Z
LAST-MODIFIED:20200222T220028Z
UID:40125-1587686400-1587772799@globalbiodefense.com
SUMMARY:Quickfire Challenge Applications Due: JLABS Pediatric Influenza Innovations
DESCRIPTION:Innovators within the fields of pediatric oncology\, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150\,000 in grant funding; one year of residency at JLABS @ Washington\, DC with the use of a bench\, workstation\, and access to the JLABS @ Washington\, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies. \nThe submission deadline is 24 April 2020. Please visit the JLABS website for more information.
URL:https://globalbiodefense.com/event/quickfire-challenge-applications-due-jlabs-pediatric-influenza-innovations/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
END:VCALENDAR